TwinBeech Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

TwinBeech Capital’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-126,758	Closed	-$4.71M	–	924
2023 Q1	$4.71M	Buy	126,758 +89,808	+243%	+$4.04M	0.1%	247
2022 Q4	$1.67M	Sell	36,950 -25,483	-41%	-$1.65M	0.03%	458
2022 Q3	$4.36M	Buy	+62,433	New	+$4.62M	0.12%	213
2022 Q2	–	Sell	-44,098	Closed	-$3.63M	–	772
2022 Q1	$3.63M	Buy	+44,098	New	+$4.51M	0.16%	172
2021 Q3	–	Sell	-14,679	Closed	-$2.37M	–	809
2021 Q2	$2.37M	Buy	14,679 +12,899	+725%	+$2.07M	0.29%	111
2021 Q1	$305K	Sell	1,780 -5,986	-77%	-$1.19M	0.04%	372
2020 Q4	$1.71M	Buy	+7,766	New	+$1.68M	0.28%	117

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

TwinBeech Capital's MRTX Position: Q2 2023 in Review

TwinBeech Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 126,758 shares — an estimated $4.71M sold.

TwinBeech Capital first reported a position in MRTX in Q4 2020 and held it in 7 quarters. The position peaked at $4.71M in Q1 2023. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

TwinBeech Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
TwinBeech Capital sold 126,758 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.71M.
TwinBeech Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
TwinBeech Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $4.71M in Q1 2023.
207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on TwinBeech Capital's 13F filing for Q2 2023, filed 14 Aug 2023.